|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A pilot trial of TAC (paclitaxel,doxorubiein,and carboplatin)chemotherapy with filgastrim support followed by radiotherapy in patients with high-risk endometrial cancer显示文摘 | Duska LR Berkowitz R Matulonis U | 2005 | Gynecol Oncol2005，96，： | 1 |
| 2 | A phase 11 trial of sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma 显示文摘 | CAMPOS S M PENSON R T MATULONIS U | 2013 | Gynecol Oncol2013，128，2： | 1 |
| 3 | A pilot trial of TAC (paclitaxe,doxorubicin,and carboplatin) chemotherapy with filgastrim support followed by radiotherapy in patients with high-risk endometrial cancer显示文摘 | Duska LR Berkowitz R Matulonis U | 2005 | Gynecol Oncol2005，96，1： | 1 |
| 4 | Phase U study of carboplatin and pemetrexed for the treatment of plati- num- sensitive recurrent ovarian cancer显示文摘 | MATULONIS U A HOROWITZ N S CAMPOS S M | 2008 | J Clin 0ncol2008，26，2： | 1 |
| 5 | A phase II trial of Suni- tinib malate in recurrent and refractory ovarian,fallopian tube and peritoneal carcinoma显示文摘 | Campos SM Penson RT Matulonis U | 2012 | Gynecol Oncol2012，9，： | 1 |
| 6 | Stereologic analysis of monocytes and their subcellular organelles in patients with acute monocytic and myelomonocytic leukemia 显示文摘 | Weiselberg L Matulonis U McGarvey E | 1990 | Lab Invest1990，63，3： | 1 |
| 7 | A phase II study of the MDR inhibitor biricodar (NCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy 显示文摘 | Seiden MV Swenerton KD Matulonis U | 2002 | Gynecol Oncol2002，86，6： | 1 |
| 8 | A pilot trial of TAC ( paclitaxe, doxombicin, and carboplatin) chemo- therapy with filgastrim support followed by radiotherapy in patients with high - risk endometrial cancer 显示文摘 | Duska LR Berkowitz R Matulonis U | 2005 | Gynecol Oncol2005，96，1： | 1 |
| 9 | Phase II, open-label, randomized, muhicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubiein in patients with BRCA1 or BRCA2 mutations and recurrent ovarian Cancer 显示文摘 | Kaye SB Lubinski J Matulonis U | 2012 | Clin Oncol2012，30，4： | 1 |
| 10 | Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian,tubal,and primary peritoneal carcinoma显示文摘 | Littell RD Hallonquist H Matulonis U | 2006 | Gynecol Oncol2006，103，2： | 1 |
| 11 | A phase Ⅱ study of the MDR inhibitor biricodar (INCEL,VX-710)and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy显示文摘 | Seiden MV Swenerton KD Matulonis U | 2002 | Gynecol Oncol2002，86，： | 1 |
| 12 | Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCAI or BRCA2 mutations and recurrent ovarian cancer显示文摘 | Kaye SB Lubinski J Matulonis U | 2012 | J Clin Oncol2012，30，： | 1 |
| 13 | A phase Ⅱ trial of modified triple doublets for the treatment of advanced Müllerian malignancies显示文摘 | Matulonis U A Campos S Krasner C | 2005 | Proc Am Soc Chin Oncol2005，23，： | 1 |
| 14 | Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian ,tubal ,and primary peritoneal carcinoma 显示文摘 | Littell RD Hallonquist H Matulonis U | 2006 | Gynecol Oncol2006，103，2： | 1 |
| 15 | A phaseⅡtrial of EMD72000(matuzumab),a humanized anti-EGFR monoclonal antibody,in patientswith platinum-resistant ovarian and primary peritoneal malignancies显示文摘 | Seiden MV Burris HA Matulonis U | 2007 | Gynecol Oncol2007，104，3： | 1 |
| 16 | New advances in ovarian cancer显示文摘 | Liu J Matulonis U A | | 0，，： | 1 |
| 17 | PARP inhibitors in ovarian cancer: current status and future promise显示文摘 | Liu J F Konstantinopoulos P A Matulonis U A | 2014 | Gynecol Oncol2014，133，2： | 1 |
| 18 | A phase Ⅱ trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies 显示文摘 | SEIDEN M V BURRIS H A MATULONIS U | 2007 | Gynecol Oncol2007，104，3： | 1 |
| 19 | Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal and primary peritoneal carcinoma 显示文摘 | Littell RD Hallonquist H Matulonis U | 2006 | Gynecol Oncol2006，103，2： | 1 |
| 20 | Phase II, open - label, randomized, muhicenter study comparing the effi cacy and safety of olaparib, a poly ( ADP - ribose) polymerase inhibitor, and pc-gylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer 显示文摘 | Kaye SB Lubinski J Matulonis U | 2012 | J Clin Oncol2012，30，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员